XXXX agonists have a sustained stimulatory effect on @entity2819 release after chronic treatment.

@entity308 @entity19 @entity20647 @entity15984 @entity2819 @entity32267 @entity148 @entity35
OBJECTIVE: @entity20647 ( @entity15984 agonists are a new group of antidiabetic medications quickly gaining popularity. We aimed to examine behavioural and neuroendocrine changes following chronic treatment with @entity15984 agonists in animal models. METHODS: The effects of chronic treatment with @entity15984 agonists were determined on behavioural parameters [ @entity148 level in the light-dark compartment test, the motor activity in automated activity cages, immobility in the forced swimming test (FST)] and on @entity2819 release in @entity19 . The possible antidepressant effect of chronic liraglutide treatment was also studied in Flinders Sensitive Line (FSL) @entity35 , a genetic model of @entity308 . RESULTS: Two weeks of treatment with exenatide (10   g /kg twice daily) or liraglutide (1200   g/kg once daily) did not affect the @entity148 level in a light-dark compartment test nor induce an antidepressant-like effect in the FST in @entity19 . Moreover, chronic treatment with liraglutide had no effect on @entity308 -related behaviour in FSL @entity35 . Interestingly, hypolocomotion induced by the drugs in @entity19 disappeared after chronic dosing. Both of the @entity15984 agonists induced robust increases in @entity2819 levels in @entity19 under basal conditions as well as in the case of combination with swimming stress. Remarkably, exenatide was as potent a stimulator of @entity2819 release after 2 weeks as after acute administration. CONCLUSIONS: The increases in @entity2819 release seen after acute exenatide or @entity32267 treatment do not abate after 2 weeks of treatment demonstrating that tolerance does not develop towards this particular effect of @entity20647 agonists.
